News & Updates

Show Multimedia Only

Rivaroxaban curbs MACE, major bleeding risks in AF patients with CAD, regardless of age

20 Aug 2025

Monotherapy with rivaroxaban in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) appears to protect against the risks of major adverse cardiovascular event (MACE) and major bleeding, with the benefit observed across the broad range of age, according to a post hoc analysis of the open-label AFIRE* trial.

Rivaroxaban curbs MACE, major bleeding risks in AF patients with CAD, regardless of age

20 Aug 2025

Smoking cessation experts from New Zealand and Malaysia come together to give their thoughts on the recent vape issues.

20 Aug 2025

Vape or e-cigarette is a rather recent arrival in the nicotine delivery route. As such, little is known about the long-term effects of vaping. However, developments in recent years have brought vaping to the limelight as it is becoming increasingly obvious that the vape industry is targeting youth. Initially unintentional, but increasingly deliberate as it became obvious that youth were a valuable source of current and future income.

Smoking cessation experts from New Zealand and Malaysia come together to give their thoughts on the recent vape issues.

20 Aug 2025

The GLP-1 RA journey: From T2D and obesity treatment to cardiorenal protection

20 Aug 2025 by

The American Heart Association defines cardiovascular-kidney-metabolic (CKM) syndrome as the overlap between metabolic, kidney, and cardiovascular diseases (CVDs). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, offer benefits that extend beyond glycaemic control and weight loss to cardiorenal protection. In a symposium, Dr Julie Lovshin of the University of Toronto, Canada, shared clinical trial data on once-weekly subcutaneous (SC) semaglutide’s cardiorenal protective effects in different CKM patient populations. She also explored characteristics of optimal candidates for GLP-1 RA treatment.

The GLP-1 RA journey: From T2D and obesity treatment to cardiorenal protection

20 Aug 2025

First experience with sotatercept for pulmonary arterial hypertension in Southern China

20 Aug 2025 by

A 77-year-old male chronic smoker with a history of diabetes mellitus, hypertension, coronary artery disease treated with stenting to left circumflex artery and ramus intermediate artery in 2015, chronic obstructive pulmonary disease (COPD), and interstitial lung disease (ILD) presented on 19 January 2024 with shortness of breath (SOB) on exertion, which began following an episode of COVID-19 in May 2023 and worsened after a subsequent COVID-19 episode in April 2024. Before the two COVID-19 episodes, the patient had good exercise tolerance and could manage a 1-hour hike.

First experience with sotatercept for pulmonary arterial hypertension in Southern China

20 Aug 2025

Select cases of advanced EGFR-mutated NSCLC with different disease burden treated with first-line osimertinib plus chemotherapy

20 Aug 2025 by

A 65-year-old male with good past health presented in June 2024 with a 1-month history of cough.

Select cases of advanced EGFR-mutated NSCLC with different disease burden treated with first-line osimertinib plus chemotherapy

20 Aug 2025

CKM syndrome: Strategies for early intervention in primary care

20 Aug 2025 by

Cardiovascular-kidney-metabolic (CKM) syndrome is a systemic, progressive disorder associated with adverse outcomes in advanced stages. At an industry-sponsored symposium organized by the Hong Kong College of Family Physicians, experts discussed recommendations in the American Heart Association’s (AHA) presidential advisory on CKM health, strategies for early CKM intervention in primary care, as well as guideline recommendations and clinical trial results supporting the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i; eg, empagliflozin) in CKM syndrome.

CKM syndrome: Strategies for early intervention in primary care

20 Aug 2025

Sotatercept: A first-in-class PAH medication approved in HK

20 Aug 2025

Sotatercept, a first-in-class activin signalling inhibitor for pulmonary arterial hypertension (PAH), is approved in Hong Kong in August 2025, following regulatory approvals in Macau, the US, and the EU in February 2025.

Sotatercept: A first-in-class PAH medication approved in HK

20 Aug 2025

The importance of consent

20 Aug 2025 by

Issues around consent are a dominant allegation in a substantial proportion of medicolegal claims handled by Medical Protection in Hong Kong in 2022. This article provides practical tips on informed consent and highlights case studies of complaints and claims handled by Medical Protection to facilitate learning.

The importance of consent

20 Aug 2025

Real-world data: FF/UMEC/VI offers clinical advantages over another 3-in-1 COPD inhaler

20 Aug 2025

Once-daily, single-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) outperforms twice-daily, single-inhaler triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BUD/GLY/ FORM) in the treatment of chronic obstructive pulmonary disease (COPD), two recent real-world comparative effectiveness studies have found.

Real-world data: FF/UMEC/VI offers clinical advantages over another 3-in-1 COPD inhaler

20 Aug 2025

Sintilimab plus axitinib shows therapeutic potential in FH-deficient RCC

19 Aug 2025

The combination of sintilimab plus axitinib demonstrates encouraging antitumour activity in patients with fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) while having a manageable safety profile, according to a phase II study conducted in China.

Sintilimab plus axitinib shows therapeutic potential in FH-deficient RCC

19 Aug 2025

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Rivaroxaban curbs MACE, major bleeding risks in AF patients with CAD, regardless of age

Rivaroxaban curbs MACE, major bleeding risks in AF patients with CAD, regardless of age

Smoking cessation experts from New Zealand and Malaysia come together to give their thoughts on the recent vape issues.

Smoking cessation experts from New Zealand and Malaysia come together to give their thoughts on the recent vape issues.

The GLP-1 RA journey: From T2D and obesity treatment to cardiorenal protection

The GLP-1 RA journey: From T2D and obesity treatment to cardiorenal protection

First experience with sotatercept for pulmonary arterial hypertension in Southern China

First experience with sotatercept for pulmonary arterial hypertension in Southern China

Select cases of advanced EGFR-mutated NSCLC with different disease burden treated with first-line osimertinib plus chemotherapy

Select cases of advanced EGFR-mutated NSCLC with different disease burden treated with first-line osimertinib plus chemotherapy

CKM syndrome: Strategies for early intervention in primary care

CKM syndrome: Strategies for early intervention in primary care

Sotatercept: A first-in-class PAH medication approved in HK

Sotatercept: A first-in-class PAH medication approved in HK

The importance of consent

The importance of consent

Real-world data: FF/UMEC/VI offers clinical advantages over another 3-in-1 COPD inhaler

Real-world data: FF/UMEC/VI offers clinical advantages over another 3-in-1 COPD inhaler

Sintilimab plus axitinib shows therapeutic potential in FH-deficient RCC

Sintilimab plus axitinib shows therapeutic potential in FH-deficient RCC